DOCSLIB.ORG

1 SUPPLEMENTAL MATERIALS Supplemental Table 1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1 SUPPLEMENTAL MATERIALS Supplemental Table 1 SUPPLEMENTAL MATERIALS Supplemental Table 1: NDC codes reflecting medications used for TF gender affirmation Label NDC Codes BICALUTAMIDE tablet 16729-023-01 BICALUTAMIDE tablet 60505-2642-1 BICALUTAMIDE tablet 0781-5409-01 BICALUTAMIDE tablet 41616-485-08 BICALUTAMIDE tablet, film coated 51991-560-01 BICALUTAMIDE tablet, film coated 65841-613-01 BICALUTAMIDE tablet, film coated 67253-191-03 BICALUTAMIDE tablet, film coated 0378-7017-93 BICALUTAMIDE tablet, film coated 16714-571-01 BICALUTAMIDE tablet, film coated 47335-485-08 BICALUTAMIDE tablet, film coated 63672-0005-0 BICALUTAMIDE tablet, film coated 0093-0220-01 BICALUTAMIDE tablet, film coated 68382-224-01 BICALUTAMIDE (bicalutamide) tablet, film coated [Repackaged] 42291-168-30 BICALUTAMIDE tablet [Repackaged] 68084-612-11 BICALUTAMIDE tablet [Repackaged] 63629-5321-1 BICALUTAMIDE tablet [Repackaged] 0904-6019-46 BICALUTAMIDE tablet, film coated [Repackaged] 69189-0298-1 BICALUTAMIDE tablet, film coated [Repackaged] 60429-177-01 BICALUTAMIDE tablet, film coated [Repackaged] 60429-226-05 BICALUTAMIDE tablet, film coated [Repackaged] 54868-6133-0 CASODEX (bicalutamide) tablet 0310-0705-10 CASODEX (bicalutamide) tablet [Repackaged] 54868-4503-0 NILANDRON (nilutamide) tablet 59212-111-10 NILANDRON (nilutamide) tablet 24987-111-14 NILANDRON (nilutamide) tablet 0088-1111-14 ALDACTONE- spironolactone tablet, film coated 0025-1001-31 AVODART (dutasteride) capsule, liquid filled 0173-0712-02 AVODART (dutasteride) capsule, liquid filled (Repackaged) 54569-6607-0 AVODART (dutasteride) capsule, liquid filled (Repackaged) 69189-0712-1 AVODART (dutasteride) capsule, liquid filled (Repackaged) 35356-210-30 1 AVODART (dutasteride) capsule, liquid filled (Repackaged) 54868-5114-0 CENESTIN - synthetic conjugated estrogens, a tablet, film coated 54868-1432-0 CLIMARA (estradiol) patch [Repackaged] 50419-451-01 CLIMARA PRO (estradiol and levonorgestrel) patch [Repackaged] 50419-491-04 CLIMARA PRO (estradiol and levonorgestrel) patch 54868-5570-0 DELESTROGEN- estradiol valerate injection 42023-110-01 ESTRADIOL VALERATE AND ESTRADIOL VALERATE/DIENOGEST kit 0781-4110-15 ESTRADIOL VALERATE injection 42023-134-01 ESTRADIOL VALERATE injection, solution 0574-0870-05 DEPO-ESTRADIOL (estradiol cypionate) injection 0009-0271-01 DEPO-ESTRADIOL (estradiol cypionate) injection [Repackaged] 54868-1729-0 DIVIGEL (estradiol) gel 0245-0880-30 DIVIGEL (estradiol) gel 68025-065-01 DIVIGEL (estradiol) gel [Repackaged] 54868-6056-0 DUTASTERIDE capsule 0591-2292-19 DUTASTERIDE capsule 65162-750-03 DUTASTERIDE capsule 51991-749-33 DUTASTERIDE capsule 0054-0395-13 DUTASTERIDE capsule, liquid filled 60505-3877-3 DUTASTERIDE capsule, liquid filled 0173-7077-00 DUTASTERIDE capsule, liquid filled 0115-1438-08 DUTASTERIDE capsule, liquid filled 62112-8068-1 DUTASTERIDE capsule, liquid filled 64980-224-03 DUTASTERIDE capsule, liquid filled 64380-763-04 DUTASTERIDE capsule, liquid filled 0093-5655-56 DUTASTERIDE (dutasteride) capsule [Repackaged] 42291-257-90 DUTASTERIDE capsule [Repackaged] 63187-657-30 DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE capsule 10370-280-09 DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE capsule 0591-3771-19 JALYN (dutasteride and tamsulosin hydrochloride) capsule 0173-0809-13 JALYN (dutasteride and tamsulosin hydrochloride) capsule 54868-6328-0 ELESTRIN (estradiol gel 0.06%) gel, metered 0037-4801-35 ELESTRIN (estradiol) gel 18860-490-02 ELESTRIN (estradiol) gel 18860-480-01 2 ENJUVIA (synthetic conjugated estrogens, b) tablet, film coated 51285-406-02 ENJUVIA (synthetic conjugated estrogens, b) tablet [Repackaged] 54868-6163-0 ESTRACE (estradiol) cream 0430-3754-14 ESTRACE (estradiol) tablet 0430-0720-24 DIVIGEL (estradiol) gel 0245-0880-30 DIVIGEL (estradiol) gel 68025-065-01 estraderm (estradiol) patch, extended release 0083-2310-08 ESTRADIOL patch 0378-4640-16 ESTRADIOL patch 0378-3349-16 ESTRADIOL patch, extended release 0781-7129-40 ESTRADIOL pellet 69761-022-01 ESTRADIOL pellet 69761-012-01 ESTRADIOL pellet 69761-020-01 ESTRADIOL pellet 69761-006-01 ESTRADIOL pellet 69761-018-01 ESTRADIOL pellet 69761-010-01 ESTRADIOL pellet 69761-025-01 ESTRADIOL pellet 69761-015-01 ESTRADIOL tablet 65162-226-21 ESTRADIOL tablet 0555-0886-02 ESTRADIOL tablet 23155-013-01 ESTRADIOL tablet 0378-1452-01 ESTRADIOL tablet 0591-0487-01 ESTRADIOL TRANSDERMAL SYSTEM (estradiol) patch 47781-204-04 GUNA-BETA-ESTRADIOL (estradiol) solution/ drops 17089-359-18 Innofem (Estradiol) tablet, film coated 0169-1842-81 DIVIGEL (estradiol) gel [Repackaged] 54868-6056-0 ESTRADIOL (estradiol) tablet [Repackaged] 50268-290-11 ESTRADIOL (estradiol) tablet [Repackaged] 43063-201-01 ESTRADIOL patch [Repackaged] 54868-4811-0 ESTRADIOL tablet [Repackaged] 54569-4908-0 ESTRADIOL tablet [Repackaged] 54569-4907-0 ESTRADIOL tablet [Repackaged] 33261-667-30 ESTRADIOL tablet [Repackaged] 69189-0886-1 3 ESTRADIOL tablet [Repackaged] 69189-0487-1 ESTRADIOL tablet [Repackaged] 69189-0899-1 ESTRADIOL tablet [Repackaged] 10544-069-30 ESTRADIOL tablet [Repackaged] 63629-2766-1 ESTRADIOL tablet [Repackaged] 63629-4788-1 ESTRADIOL tablet [Repackaged] 63629-3755-1 ESTRADIOL tablet [Repackaged] 63629-5208-1 ESTRADIOL tablet [Repackaged] 55154-6242-0 ESTRADIOL tablet [Repackaged] 61919-278-30 ESTRADIOL tablet [Repackaged] 61919-198-30 ESTRADIOL tablet [Repackaged] 60429-327-01 ESTRADIOL tablet [Repackaged] 0179-0123-70 ESTRADIOL tablet [Repackaged] 0179-0073-70 ESTRADIOL tablet [Repackaged] 0179-1999-01 ESTRADIOL tablet [Repackaged] 49999-083-30 ESTRADIOL tablet [Repackaged] 43063-446-01 ESTRADIOL tablet [Repackaged] 43063-651-30 ESTRADIOL tablet [Repackaged] 55289-761-01 ESTRADIOL tablet [Repackaged] 55289-603-07 ESTRADIOL tablet [Repackaged] 54868-4030-0 ESTRADIOL tablet [Repackaged] 68788-9901-1 ESTRADIOL tablet [Repackaged] 68788-9416-1 ESTRADIOL tablet [Repackaged] 63187-482-30 ESTRADIOL tablet [Repackaged] 64205-048-30 ESTRADIOL tablet [Repackaged] 21695-613-00 ESTRADIOL tablet [Repackaged] 16590-278-30 ESTRADIOL tablet [Repackaged] 16590-052-71 AX PHARMACEUTICAL (estradiol) powder 62157-007-02 ESTROGEN PHENOLIC (estradiol,) liquid 44911-0199-1 MENOSTAR (estradiol) patch [Repackaged] 50419-455-04 VAGIFEM (estradiol) tablet, film coated [Repackaged] 54868-6182-0 VIVELLE DOT - estradiol patch, extended release [Repackaged] 54868-4242-0 ESTRADIOL / NORETHINDRONE ACETATE (estradiol and norethindrone acetate) tablet, film coated 51991-474-28 4 ESTRADIOL / NORETHINDRONE ACETATE (estradiol and norethindrone acetate) tablet, film coated [Repackaged] 54868-4677-0 ESTROSTEP FE (norethindrone acetate and ethinyl estradiol and ferrous fumarate) kit 0430-0570-14 ESTROSTEP FE (norethindrone acetate and ethinyl estradiol and ferrous fumarate) kit 0430-0005-31 GILDESS 24 FE (norethindrone acetate and ethinyl estradiol and ferrous fumarate) 0603-7610-01 GILDESS FE 1.5/30 (norethindrone acetate, ethinyl estradiol and ferrous fumarate) kit 0603-7608-01 GILDESS FE 1/20 (norethindrone acetate, ethinyl estradiol and ferrous fumarate) kit 0603-7609-01 JUNEL FE 24 (norethindrone acetate and ethinyl estradiol and ferrous fumarate) kit 0093-5328-28 LO LOESTRIN FE (norethindrone acetate and ethinyl estradiol, ethinyl estradiol and ferrous fumarate) kit 0430-0420-14 LOESTRIN 24 FE (norethindrone acetate and ethinyl estradiol, and ferrous fumarate) kit 0430-0530-14 MICROGESTIN 24 FE (norethindrone acetate and ethinyl estradiol and ferrous fumarate) kit 52544-167-31 MINASTRIN 24 FE (norethindrone acetate and ethinyl estradiol, and ferrous fumarate) kit 0430-0535-14 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL ( norethindrone acetate and ethinyl estradiol ) kit 0378-7283-53 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL ( norethindrone acetate and ethinyl estradiol ) kit 0378-7301-53 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE ('', and '', and '') kit 0430-0539-14 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL tablet 68462-656-29 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL tablet 68462-132-79 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL tablet 0378-7280-53 TARINA FE 1/20 (norethindrone acetate and ethinyl estradiol) kit 50102-128-01 TILIA FE (norethindrone acetate and ethinyl estradiol) kit 52544-054-31 TILIA FE (norethindrone acetate and ethinyl estradiol, and ferrous fumarate) kit 52544-175-72 LOESTRIN 24 FE (norethindrone acetate and ethinyl estradiol, and ferrous fumarate) kit [Repackaged] 54868-6100-0 BLISOVI 24 FE (norethindrone acetate and ethinyl estradiol) kit 68180-864-11 BLISOVI FE 1.5/30 (norethindrone acetate and ethinyl estradiol) kit 68180-866-11 BLISOVI FE 1/20 (norethindrone acetate and ethinyl estradiol) kit 68180-865-11 FYAVOLV (norethindrone acetate and ethinyl estradiol) tablet, film coated 68180-827-09 GILDESS 1.5/30 (norethindrone acetate and ethinyl estradiol) tablet, film coated 0603-7606-02 GILDESS 1/20 (norethindrone acetate and ethinyl estradiol) tablet, film coated 0603-7607-02 JEVANTIQUE LO (norethindrone acetate and ethinyl estradiol) tablet 52544-236-31 JINTELI (norethindrone acetate and ethinyl estradiol) tablet 0093-3122-28 5 JUNEL 1/20 (norethindrone acetate and ethinyl estradiol) tablet 0555-9025-42 JUNEL 1.5/30 (norethindrone acetate and ethinyl estradiol) tablet 0555-9026-58 JUNEL FE 1/20 (norethindrone acetate and ethinyl estradiol, and ferrous fumarate) kit 0555-9027-42 JUNEL FE 1.5/30 (norethindrone acetate and ethinyl estradiol, and ferrous fumarate) kit 0555-9028-58 LARIN 1.5/30 (norethindrone acetate/ethinyl estradiol) kit 16714-407-01 LARIN 1/20 (norethindrone acetate/ethinyl estradiol) kit 16714-408-01 LARIN 24 FE
Load more

Recommended publications
  • PPE Requirements Hazardous Drug Handling
    This document’s purpose is only to provide general guidance. It is not a definitive interpretation for how to comply with DOSH requirements. Consult the actual NIOSH hazardous drugs list and program regulations in entirety to understand all specific compliance requirements. Minimum PPE Required Minimum PPE Required Universal (Green) - handling and disposed of using normal precautions. PPE Requirements High (Red) - double gloves, gown, eye and face protection in Low (Yellow) - handle at all times with gloves and appropriate engineering Hazardous Drug Handling addition to any necessary controls. engineering controls. Moderate (Orange) -handle at all times with gloves, gown, eye and face protection (with splash potential) and appropirate engineering controls. Tablet Open Capsule Handling only - Contained Crush/Split No alteration Crush/Split Dispensed/Common Drug Name Other Drug Name Additional Information (Formulation) and (NIOSH CATEGORY #) Minimum PPE Minimum PPE Minimum PPE Minimum PPE Required required required required abacavir (susp) (2) ziagen/epzicom/trizivir Low abacavir (tablet) (2) ziagen/epzicom/trizivir Universal Low Moderate acitretin (capsule) (3) soriatane Universal Moderate anastrazole (tablet) (1) arimidex Low Moderate High android (capsule) (3) methyltestosterone Universal Moderate apomorphine (inj sq) (2) apomorphine Moderate arthotec/cytotec (tablet) (3) diclofenac/misoprostol Universal Low Moderate astagraf XL (capsule) (2) tacrolimus Universal do not open avordart (capsule) (3) dutasteride Universal Moderate azathioprine
    [Show full text]
  • Ocps) Used in the NM Family Planning Program (FPP
    The following slides are intended to familiarize nurses and clinicians with oral contraceptive pills (OCPs) used in the NM Family Planning Program (FPP). The FPP does not intend for this information to supersede the Family Planning Protocol particularly on the requirement for Public Health Nurses in the Public Health Offices to consult a clinician as stated in the Protocol when in doubt or if it is necessary to switch the client’s OCP type. 1 2 Combined oral contraceptives (COCs) contain two hormones; estrogen and progestin. In general, any combined OCP is good for most women who are eligible to take estrogen according to the CDC U.S. Medical Eligibility Criteria (MEC). Once again, refer to the US MEC chart to find out if OCP is a suitable choice for clients with specific health conditions. To learn a little bit about what each hormone does, the FPP is providing the following summary: Estrogen: provides endometrial stability = menstrual cycle control. A higher estrogen dose increases the venous thromboembolism (VTE) or clot risk but OCP clot risk is still less harmful than the clot risk related to pregnancy and giving birth. Progestin: provides most of the contraceptive effect by ‐Preventing luteinizing hormone (LH) surge /ovulation ‐Thickening the cervical mucus to prevent sperm entry. Two major OCP formations are available. Monophasic: There is only one dose of estrogen and progestin in each active pill in the packet; and Multiphasic: There are varying doses of hormones, particularly progestin in the active pills. 3 Section 3 of the FPP Protocol contains the OCP Substitute Table, which groups OCPs into 6 classes according to the estrogen dosage, the type of progestin and the formulations.
    [Show full text]
  • Download PDF File
    Ginekologia Polska 2019, vol. 90, no. 9, 520–526 Copyright © 2019 Via Medica ORIGINAL PAPER / GYNECologY ISSN 0017–0011 DOI: 10.5603/GP.2019.0091 Anti-androgenic therapy in young patients and its impact on intensity of hirsutism, acne, menstrual pain intensity and sexuality — a preliminary study Anna Fuchs, Aleksandra Matonog, Paulina Sieradzka, Joanna Pilarska, Aleksandra Hauzer, Iwona Czech, Agnieszka Drosdzol-Cop Department of Pregnancy Pathology, Department of Woman’s Health, School of Health Sciences in Katowice, Medical University of Silesia, Katowice, Poland ABSTRACT Objectives: Using anti-androgenic contraception is one of the methods of birth control. It also has a significant, non-con- traceptive impact on women’s body. These drugs can be used in various endocrinological disorders, because of their ability to reduce the level of male hormones. The aim of our study is to establish a correlation between taking different types of anti-androgenic drugs and intensity of hirsutism, acne, menstrual pain intensity and sexuality . Material and methods: 570 women in childbearing age that had been using oral contraception for at least three months took part in our research. We examined women and asked them about quality of life, health, direct causes and effects of that treatment, intensity of acne and menstrual pain before and after. Our research group has been divided according to the type of gestagen contained in the contraceptive pill: dienogest, cyproterone, chlormadynone and drospirenone. Ad- ditionally, the control group consisted of women taking oral contraceptives without antiandrogenic component. Results: The mean age of the studied group was 23 years ± 3.23. 225 of 570 women complained of hirsutism.
    [Show full text]
  • CASODEX (Bicalutamide)
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Gynecomastia and breast pain have been reported during treatment with These highlights do not include all the information needed to use CASODEX 150 mg when used as a single agent. (5.3) CASODEX® safely and effectively. See full prescribing information for • CASODEX is used in combination with an LHRH agonist. LHRH CASODEX. agonists have been shown to cause a reduction in glucose tolerance in CASODEX® (bicalutamide) tablet, for oral use males. Consideration should be given to monitoring blood glucose in Initial U.S. Approval: 1995 patients receiving CASODEX in combination with LHRH agonists. (5.4) -------------------------- RECENT MAJOR CHANGES -------------------------- • Monitoring Prostate Specific Antigen (PSA) is recommended. Evaluate Warnings and Precautions (5.2) 10/2017 for clinical progression if PSA increases. (5.5) --------------------------- INDICATIONS AND USAGE -------------------------- ------------------------------ ADVERSE REACTIONS ----------------------------- • CASODEX 50 mg is an androgen receptor inhibitor indicated for use in Adverse reactions that occurred in more than 10% of patients receiving combination therapy with a luteinizing hormone-releasing hormone CASODEX plus an LHRH-A were: hot flashes, pain (including general, back, (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of pelvic and abdominal), asthenia, constipation, infection, nausea, peripheral the prostate. (1) edema, dyspnea, diarrhea, hematuria, nocturia, and anemia. (6.1) • CASODEX 150 mg daily is not approved for use alone or with other treatments. (1) To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca Pharmaceuticals LP at 1-800-236-9933 or FDA at 1-800-FDA-1088 or ---------------------- DOSAGE AND ADMINISTRATION ---------------------- www.fda.gov/medwatch The recommended dose for CASODEX therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening).
    [Show full text]
  • Steroids 78 (2013) 44–52
    Steroids 78 (2013) 44–52 Contents lists available at SciVerse ScienceDirect Steroids journal homepage: www.elsevier.com/locate/steroids Alternative long-term markers for the detection of methyltestosterone misuse ⇑ C. Gómez a,b, O.J. Pozo a, J. Marcos a,b, J. Segura a,b, R. Ventura a,b, a Bioanalysis Research Group, IMIM-Hospital del Mar, Barcelona, Spain b Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain article info abstract Article history: Methyltestosterone (MT) is one of the most frequently detected anabolic androgenic steroids in doping Received 21 May 2012 control analysis. MT misuse is commonly detected by the identification of its two main metabolites Received in revised form 28 September excreted as glucuronide conjugates, 17a-methyl-5a-androstan-3a,17b-diol and 17a-methyl-5b-andro- 2012 stan-3a,17b-diol. The detection of these metabolites is normally performed by gas chromatography–mass Accepted 10 October 2012 spectrometry, after previous hydrolysis with b-glucuronidase enzymes, extraction and derivatization Available online 2 November 2012 steps. The aim of the present work was to study the sulphate fraction of MT and to evaluate their potential to improve the detection of the misuse of the drug in sports. MT was administered to healthy volunteers Keywords: and urine samples were collected up to 30 days after administration. After an extraction with ethyl ace- Methyltestosterone Sulphate tate, urine extracts were analysed by liquid chromatography tandem mass spectrometry using electro- Metabolism spray ionisation in negative mode by monitoring the transition m/z 385 to m/z 97. Three diol sulphate LC–MS/MS metabolites (S1, S2 and S3) were detected.
    [Show full text]
  • COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone During SARS-Cov-2 Infection
    pharmaceuticals Review COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection Katarzyna Kotfis 1,* , Kacper Lechowicz 1 , Sylwester Drozd˙ zal˙ 2 , Paulina Nied´zwiedzka-Rystwej 3 , Tomasz K. Wojdacz 4, Ewelina Grywalska 5 , Jowita Biernawska 6, Magda Wi´sniewska 7 and Miłosz Parczewski 8 1 Department of Anesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland; [email protected] 2 Department of Pharmacokinetics and Monitored Therapy, Pomeranian Medical University, 70-111 Szczecin, Poland; [email protected] 3 Institute of Biology, University of Szczecin, 71-412 Szczecin, Poland; [email protected] 4 Independent Clinical Epigenetics Laboratory, Pomeranian Medical University, 71-252 Szczecin, Poland; [email protected] 5 Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, 20-093 Lublin, Poland; [email protected] 6 Department of Anesthesiology and Intensive Therapy, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland; [email protected] 7 Clinical Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, 70-111 Szczecin, Poland; [email protected] 8 Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University in Szczecin, 71-455 Szczecin, Poland; [email protected] * Correspondence: katarzyna.kotfi[email protected]; Tel.: +48-91-466-11-44 Abstract: In March 2020, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 was declared Citation: Kotfis, K.; Lechowicz, K.; a global pandemic by the World Health Organization (WHO). The clinical course of the disease is Drozd˙ zal,˙ S.; Nied´zwiedzka-Rystwej, unpredictable but may lead to severe acute respiratory infection (SARI) and pneumonia leading to P.; Wojdacz, T.K.; Grywalska, E.; acute respiratory distress syndrome (ARDS).
    [Show full text]
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
    [Show full text]
  • Comparing the Effects of Combined Oral Contraceptives Containing Progestins with Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis In
    JMIR RESEARCH PROTOCOLS Amiri et al Review Comparing the Effects of Combined Oral Contraceptives Containing Progestins With Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis in Patients With Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis Mina Amiri1,2, PhD, Postdoc; Fahimeh Ramezani Tehrani2, MD; Fatemeh Nahidi3, PhD; Ali Kabir4, MD, MPH, PhD; Fereidoun Azizi5, MD 1Students Research Committee, School of Nursing and Midwifery, Department of Midwifery and Reproductive Health, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 2Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 3School of Nursing and Midwifery, Department of Midwifery and Reproductive Health, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 4Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Islamic Republic Of Iran 5Endocrine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran Corresponding Author: Fahimeh Ramezani Tehrani, MD Reproductive Endocrinology Research Center Research Institute for Endocrine Sciences Shahid Beheshti University of Medical Sciences 24 Parvaneh Yaman Street, Velenjak, PO Box 19395-4763 Tehran, 1985717413 Islamic Republic Of Iran Phone: 98 21 22432500 Email: [email protected] Abstract Background: Different products of combined oral contraceptives (COCs) can improve clinical and biochemical findings in patients with polycystic ovary syndrome (PCOS) through suppression of the hypothalamic-pituitary-gonadal (HPG) axis. Objective: This systematic review and meta-analysis aimed to compare the effects of COCs containing progestins with low androgenic and antiandrogenic activities on the HPG axis in patients with PCOS.
    [Show full text]
  • How to Select Pharmacologic Treatments to Manage Recidivism Risk in Sex Off Enders
    How to select pharmacologic treatments to manage recidivism risk in sex off enders Consider patient factors when choosing off -label hormonal and nonhormonal agents ® Dowden Healthex offenders Media traditionally are managed by the criminal justice system, but psychiatrists are fre- Squently called on to assess and treat these indi- CopyrightFor personalviduals. use Part only of the reason is the overlap of paraphilias (disorders of sexual preference) and sexual offending. Many sexual offenders do not meet DSM criteria for paraphilias,1 however, and individuals with paraphil- ias do not necessarily commit offenses or come into contact with the legal system. As clinicians, we may need to assess and treat a wide range of sexual issues, from persons with paraphilias who are self-referred and have no legal involvement, to recurrent sexual offenders who are at a high risk of repeat offending. Successfully managing sex offenders includes psychological and pharmacologic interven- 2009 © CORBIS / TIM PANNELL 2009 © CORBIS / tions and possibly incarceration and post-incarceration Bradley D. Booth, MD surveillance. This article focuses on pharmacologic in- Assistant professor terventions for male sexual offenders. Department of psychiatry Director of education Integrated Forensics Program University of Ottawa Reducing sexual drive Ottawa, ON, Canada Sex offending likely is the result of a complex inter- play of environment and psychological and biologic factors. The biology of sexual function provides nu- merous targets for pharmacologic intervention, in- cluding:2 • endocrine factors, such as testosterone • neurotransmitters, such as serotonin. The use of pharmacologic treatments for sex of- fenders is off-label, and evidence is limited. In general, Current Psychiatry 60 October 2009 pharmacologic treatments are geared toward reducing For mass reproduction, content licensing and permissions contact Dowden Health Media.
    [Show full text]
  • PMBJP Product.Pdf
    Sr. Drug Generic Name of the Medicine Unit Size MRP Therapeutic Category No. Code Analgesic & Antipyretic / Muscle 1 1 Aceclofenac 100mg and Paracetamol 325 mg Tablet 10's 10's 8.00 relaxants Analgesic & Antipyretic / Muscle 2 2 Aceclofenac Tablets IP 100mg 10's 10's 4.37 relaxants Acetaminophen 325 + Tramadol Hydrochloride 37.5 film Analgesic & Antipyretic / Muscle 3 4 10's 8.00 coated Tablet 10's relaxants Analgesic & Antipyretic / Muscle 4 5 ASPIRIN Tablets IP 150 mg 14's 14's 2.70 relaxants DICLOFENAC 50 mg+ PARACETAMOL 325 mg+ Analgesic & Antipyretic / Muscle 5 6 10's 11.30 CHLORZOXAZONE 500 mg Tablets 10's relaxants Diclofenac Sodium 50mg + Serratiopeptidase 10mg Tablet Analgesic & Antipyretic / Muscle 6 8 10's 12.00 10's relaxants Analgesic & Antipyretic / Muscle 7 9 Diclofenac Sodium (SR) 100 mg Tablet 10's 10's 6.12 relaxants Analgesic & Antipyretic / Muscle 8 10 Diclofenac Sodium 25mg per ml Inj. IP 3 ml 3 ml 2.00 relaxants Analgesic & Antipyretic / Muscle 9 11 Diclofenac Sodium 50 mg Tablet 10's 10's 2.90 relaxants Analgesic & Antipyretic / Muscle 10 12 Etoricoxilb Tablets IP 120mg 10's 10's 33.00 relaxants Analgesic & Antipyretic / Muscle 11 13 Etoricoxilb Tablets IP 90mg 10's 10's 25.00 relaxants Analgesic & Antipyretic / Muscle 12 14 Ibuprofen 400 mg + Paracetamol 325 mg Tablet 10's 15's 5.50 relaxants Analgesic & Antipyretic / Muscle 13 15 Ibuprofen 200 mg film coated Tablet 10's 10's 1.80 relaxants Analgesic & Antipyretic / Muscle 14 16 Ibuprofen 400 mg film coated Tablet 10's 15's 3.50 relaxants Analgesic & Antipyretic
    [Show full text]
  • ORTHO TRI-CYCLEN® TABLETS ORTHO-CYCLEN® TABLETS (Norgestimate/Ethinyl Estradiol)
    PHYSICIANS' PACKAGE INSERT ORTHO TRI-CYCLEN® TABLETS ORTHO-CYCLEN® TABLETS (norgestimate/ethinyl estradiol) Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases. DESCRIPTION Each of the following products is a combination oral contraceptive containing the progestational compound norgestimate and the estrogenic compound ethinyl estradiol. ORTHO TRI-CYCLEN 21 Tablets and ORTHO TRI-CYCLEN 28 Tablets. Each white tablet contains 0.180 mg of the progestational compound, norgestimate (18,19-Dinor- 17-pregn-4-en-20-yn-3-one,17-(acetyloxy)-13-ethyl-, oxime,(17α)-(+)-) and 0.035 mg of the estrogenic compound, ethinyl estradiol (19-nor-17α-pregna,1,3,5(10)-trien-20-yne-3,17-diol). Inactive ingredients include lactose, magnesium stearate, and pregelatinized starch. Each light blue tablet contains 0.215 mg of the progestational compound norgestimate (18,19- Dinor-17-pregn-4-en-20-yn-3-one,17-(acetyloxy)-13-ethyl-,oxime,(17α)-(+)-) and 0.035 mg of the estrogenic compound, ethinyl estradiol (19-nor-17α-pregna,1,3,5(10)-trien-20-yne-3,17-diol). Inactive ingredients include FD & C Blue No. 2 Aluminum Lake, lactose, magnesium stearate, and pregelatinized starch. Each blue tablet contains 0.250 mg of the progestational compound norgestimate (18,19-Dinor-17- pregn-4-en-20-yn-3-one, 17-(acetyloxy)-13-ethyl-,oxime,(17α)-(+)-) and 0.035 mg of the estrogenic compound, ethinyl estradiol (19-nor-17α-pregna,1,3,5(10)-trien-20-yne-3,17-diol). Inactive ingredients include FD & C Blue No. 2 Aluminum Lake, lactose, magnesium stearate, and pregelatinized starch.
    [Show full text]
  • Degradation of Doping-Relevant Steroids by Rh. Erythropolis
    In: W Schänzer, H Geyer, A Gotzmann, U Mareck (eds.) Recent Advances In Doping Analysis (15). Sport und Buch Strauß - Köln 2007 J. Grosse1), C. Rautenberg1), L. Wassill2), D. Ganghofner2), D. Thieme3) Degradation of doping-relevant Steroids by Rh. Erythropolis 1) Institute of Doping Analysis and Sports Biochemistry, D-01731 Kreischa, Germany 2) Amplex Diagnostics GmbH, D-80337 Munich, Germany 3) Institute of Legal Medicine, D-80337 Munich, Germany Introduction Former studies have shown that steroids are potential substrates for microorganisms [1]. As an example, the degradation of testosterone induced by Rhodococcus erythropolis was observed. The formation of 4-androstene-3,17-dione, 1,4-androstadiene-3,17-dione (boldione) and 1,4-androstadiene-17β-hydroxy-3-one (boldenone) was confirmed [2]. Consequently a potential endogenous origin of boldenone and its metabolites has to be taken into consideration for the evaluation of routine doping control samples revealing the presence of these substances at low concentration level [3, 4]. This work presents results obtained from further studies related to the microbial conversion of steroid substrates being relevant in doping analysis. For this purpose incubation by Rh. erythropolis was applied to examine the influence of structural variations (A/B-ring structure, substitution at position 17, conjugation) on the initial steps of the degradation pathway. Experimental Rh. erythropolis culture grown on agar plate “Mueller-Hinton” was utilised. Altogether 16 substrates (see table 1) were examined in this study. The experiments were carried out in a blank urine of a male infant spiked with 1 µg/mL of the selected substrate. Two aliquots of each sample were prepared, one control without addition and one „active“ sample with addition of bacteria solution, and incubated at 30°C for 24 hours.
    [Show full text]